Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + nedaplatin + camrelizumab for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2100048462Phase 2Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and nedaplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoint: objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxelnedaplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100048462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048462.